Jump to content

Kim L. O'Neill

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dicklyon (talk | contribs) at 05:59, 30 November 2022 (case fix (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Kim L. O'Neill is the developer of a monoclonal antibody that allows for the accurate, cheap and easy detection of cancer.

O'Neill has a B.Sc. degree from New University of Ulster and a Ph.D. from the University of Ulster. He is a full professor of microbiology at Brigham Young University. In 1998 research by O'Neill suggested a link between caffeine and the formation of some cancers.[1] O'Neill has served as associate director of BYU's cancer research center.

O'Neill is also a convert to the Church of Jesus Christ of Latter-day Saints, having joined the church in Ireland.

Sources